Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a ...

While Fujifilm has deep roots in the life sciences industry through its history working with X-ray film and diagnostic ...

The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...

Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...

AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space. | In this week's Asia news recap, AbbVie struck a big ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...